Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ: ARTV · Real-Time Price · USD
2.100
+0.140 (7.14%)
At close: Jun 6, 2025, 4:00 PM
2.110
+0.010 (0.48%)
After-hours: Jun 6, 2025, 4:15 PM EDT
Artiva Biotherapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Cash & Equivalents | 30.4 | 40.24 | 53.5 | 102.53 | 160.92 | 25.44 | Upgrade
|
| Short-Term Investments | 135.56 | 145.19 | 23.47 | - | - | - | Upgrade
|
| Cash & Short-Term Investments | 165.96 | 185.43 | 76.97 | 102.53 | 160.92 | 25.44 | Upgrade
|
| Cash Growth | 167.10% | 140.91% | -24.93% | -36.29% | 532.51% | 1259.08% | Upgrade
|
| Accounts Receivable | - | - | 1.03 | 0.53 | 0.47 | - | Upgrade
|
| Other Receivables | 0.23 | 1.05 | 0.82 | - | - | - | Upgrade
|
| Receivables | 0.23 | 1.05 | 1.86 | 0.53 | 0.47 | - | Upgrade
|
| Prepaid Expenses | 3.81 | 2.16 | 0.99 | 1.62 | 0.9 | 0.67 | Upgrade
|
| Total Current Assets | 170 | 188.63 | 79.82 | 104.68 | 162.29 | 26.11 | Upgrade
|
| Property, Plant & Equipment | 20.79 | 20.43 | 24.64 | 27.62 | 4.08 | 2.39 | Upgrade
|
| Long-Term Deferred Charges | - | - | - | - | 3.17 | 0.59 | Upgrade
|
| Other Long-Term Assets | 0.47 | 0.53 | 0.65 | 0.76 | 0.39 | 0.14 | Upgrade
|
| Total Assets | 191.26 | 209.58 | 105.11 | 133.05 | 169.93 | 29.23 | Upgrade
|
| Accounts Payable | 2.04 | 1.12 | 0.61 | 1.1 | 1.44 | 2.15 | Upgrade
|
| Accrued Expenses | 6.38 | 7.39 | 8.02 | 10.15 | 10.13 | 3.16 | Upgrade
|
| Current Portion of Leases | 3.72 | 3.74 | 3.6 | 3.49 | 0.43 | 0.46 | Upgrade
|
| Current Unearned Revenue | - | - | - | 10.89 | 7.3 | - | Upgrade
|
| Total Current Liabilities | 12.2 | 12.25 | 12.23 | 25.63 | 19.31 | 5.76 | Upgrade
|
| Long-Term Leases | 10.28 | 10.61 | 13.32 | 15.96 | 1.31 | 1.66 | Upgrade
|
| Long-Term Unearned Revenue | - | - | - | 15.64 | 21.68 | - | Upgrade
|
| Other Long-Term Liabilities | - | 0.07 | 25.17 | 0.12 | 0.08 | 5.31 | Upgrade
|
| Total Liabilities | 22.48 | 22.94 | 50.72 | 57.34 | 42.37 | 12.73 | Upgrade
|
| Common Stock | 0 | 0 | - | - | - | - | Upgrade
|
| Additional Paid-In Capital | 435.78 | 433.45 | 18.99 | 11.9 | 4.95 | 0.41 | Upgrade
|
| Retained Earnings | -267 | -246.68 | -181.31 | -152.59 | -93.8 | -21.98 | Upgrade
|
| Comprehensive Income & Other | - | -0.13 | 0.31 | - | - | - | Upgrade
|
| Total Common Equity | 168.78 | 186.64 | -162.02 | -140.7 | -88.86 | -21.57 | Upgrade
|
| Shareholders' Equity | 168.78 | 186.64 | 54.4 | 75.72 | 127.56 | 16.5 | Upgrade
|
| Total Liabilities & Equity | 191.26 | 209.58 | 105.11 | 133.05 | 169.93 | 29.23 | Upgrade
|
| Total Debt | 14 | 14.35 | 16.91 | 19.45 | 1.74 | 2.12 | Upgrade
|
| Net Cash (Debt) | 151.97 | 171.07 | 60.06 | 83.08 | 159.18 | 23.33 | Upgrade
|
| Net Cash Growth | 231.26% | 184.84% | -27.71% | -47.81% | 582.42% | - | Upgrade
|
| Net Cash Per Share | 8.87 | 15.19 | 74.82 | 108.36 | 232.10 | 36.94 | Upgrade
|
| Filing Date Shares Outstanding | 24.36 | 24.36 | 0.81 | 0.77 | 0.71 | 0.73 | Upgrade
|
| Total Common Shares Outstanding | 24.36 | 24.29 | 0.81 | 0.77 | 0.71 | 0.73 | Upgrade
|
| Working Capital | 157.8 | 176.38 | 67.59 | 79.05 | 142.98 | 20.34 | Upgrade
|
| Book Value Per Share | 6.93 | 7.68 | -200.07 | -183.50 | -124.96 | -29.71 | Upgrade
|
| Tangible Book Value | 168.78 | 186.64 | -162.02 | -140.7 | -88.86 | -21.57 | Upgrade
|
| Tangible Book Value Per Share | 6.93 | 7.68 | -200.07 | -183.50 | -124.96 | -29.71 | Upgrade
|
| Machinery | 13.12 | 11.88 | 11.24 | - | 2.78 | 0.53 | Upgrade
|
| Leasehold Improvements | 0.47 | 0.41 | 0.39 | - | 0.04 | 0.04 | Upgrade
|
Updated May 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.